LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

Search

REVOLUTION Medicines Inc

Suletud

SektorTervishoid

37.29 -1.22

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

36.91

Max

38.09

Põhinäitajad

By Trading Economics

Sissetulek

-19M

-213M

Aktsiakasum

-1.13

Kasumimarginaal

-74.379

Töötajad

616

EBITDA

-24M

-237M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+83.88% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-126M

7.5B

Eelmine avamishind

38.51

Eelmine sulgemishind

37.29

Uudiste sentiment

By Acuity

69%

31%

347 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

REVOLUTION Medicines Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. juuni 2025, 23:49 UTC

Tulu

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. juuni 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. juuni 2025, 21:30 UTC

Tulu

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Tulu

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. juuni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. juuni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. juuni 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. juuni 2025, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. juuni 2025, 23:30 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. juuni 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. juuni 2025, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. juuni 2025, 22:06 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:15 UTC

Tulu

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. juuni 2025, 21:07 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. juuni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 20:52 UTC

Tulu

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. juuni 2025, 20:51 UTC

Tulu

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

REVOLUTION Medicines Inc Prognoos

Hinnasiht

By TipRanks

83.88% tõus

12 kuu keskmine prognoos

Keskmine 70.63 USD  83.88%

Kõrge 80 USD

Madal 57 USD

Põhineb 10 Wall Streeti analüütiku instrumendi REVOLUTION Medicines Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

40.67 / 41.96Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

347 / 380 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.